Last reviewed · How we verify
Atu027
At a glance
| Generic name | Atu027 |
|---|---|
| Sponsor | Silence Therapeutics GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) (PHASE1, PHASE2)
- Study With Atu027 in Patients With Advanced Solid Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atu027 CI brief — competitive landscape report
- Atu027 updates RSS · CI watch RSS
- Silence Therapeutics GmbH portfolio CI